| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stephen M Day, Wenzhong Yang, Sarah Ewin, Xueyan Zhou, Tao M. Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide enhances hippocampal long-term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation. Hippocampus. vol 27. issue 12. 2018-07-05. PMID:28833775. |
glucagon-like peptide-1 (glp-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion. |
2018-07-05 |
2023-08-13 |
mouse |
| Y Inabu, A Saegusa, K Inouchi, S Koike, M Oba, T Sugin. Plasma concentrations of glucagon-like peptide 1 and 2 in calves fed calf starters containing lactose. Journal of dairy science. vol 100. issue 11. 2018-07-05. PMID:28888594. |
blood samples were obtained weekly from 1 to 11 wk of age, and used to measure plasma glp-1, glp-2, and insulin concentrations, serum β-hydroxybutyrate (bhb) concentration, and blood glucose concentration. |
2018-07-05 |
2023-08-13 |
Not clear |
| Y Inabu, A Saegusa, K Inouchi, S Koike, M Oba, T Sugin. Plasma concentrations of glucagon-like peptide 1 and 2 in calves fed calf starters containing lactose. Journal of dairy science. vol 100. issue 11. 2018-07-05. PMID:28888594. |
furthermore, the plasma glp-1 concentration was positively correlated with the insulin concentration (r = 0.793). |
2018-07-05 |
2023-08-13 |
Not clear |
| Davide Zanchi, Antoinette Depoorter, Laura Egloff, Sven Haller, Laura Mählmann, Undine E Lang, Jürgen Drewe, Christoph Beglinger, André Schmidt, Stefan Borgward. The impact of gut hormones on the neural circuit of appetite and satiety: A systematic review. Neuroscience and biobehavioral reviews. vol 80. 2018-07-03. PMID:28669754. |
we systematically looked into functional and neurochemical brain imaging studies investigating how key molecules such as ghrelin, glucagon-like peptide-1 (glp-1), peptide tyrosine-tyrosine (pyy), cholecystokinin (cck), leptin, glucose and insulin influence the function of brain regions regulating appetite and satiety. |
2018-07-03 |
2023-08-13 |
human |
| Davide Zanchi, Antoinette Depoorter, Laura Egloff, Sven Haller, Laura Mählmann, Undine E Lang, Jürgen Drewe, Christoph Beglinger, André Schmidt, Stefan Borgward. The impact of gut hormones on the neural circuit of appetite and satiety: A systematic review. Neuroscience and biobehavioral reviews. vol 80. 2018-07-03. PMID:28669754. |
in contrast, the plasma levels of glucose, insulin, leptin, pyy, glp-1 affect the same brain regions conversely. |
2018-07-03 |
2023-08-13 |
human |
| Choon Sang Bae, Juhyun Son. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. International journal of molecular sciences. vol 18. issue 11. 2018-07-03. PMID:29165354. |
the role of glucagon-like peptide 1 (glp1) in type 3 diabetes: glp-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain. |
2018-07-03 |
2023-08-13 |
Not clear |
| Anton M Pluschke, Barbara A Williams, Dagong Zhang, Stephen T Anderson, Eugeni Roura, Michael J Gidle. Male grower pigs fed cereal soluble dietary fibres display biphasic glucose response and delayed glycaemic response after an oral glucose tolerance test. PloS one. vol 13. issue 3. 2018-06-29. PMID:29494594. |
postprandial blood samples were used to determine plasma glucose, insulin, non-esterified fatty acids (nefa), glucose-dependent insulinotropic polypeptide (gip), glucagon-like peptide-1 (glp-1), peptide tyrosine tyrosine (pyy), ghrelin, glucagon and cortisol concentrations. |
2018-06-29 |
2023-08-13 |
Not clear |
| Gulzar Ahmad Bhat, Haseeb A Khan, Abdullah S Alhomida, Poonam Sharma, Rambir Singh, Bilal Ahmad Para. GLP-I secretion in healthy and diabetic Wistar rats in response to aqueous extract of Momordica charantia. BMC complementary and alternative medicine. vol 18. issue 1. 2018-06-29. PMID:29776414. |
the objective of this study was to assess the effect of aqueous extract of momordica charantia (aemc) on fasting blood glucose (fbg), tissue glycogen, glycosylated haemoglobin, plasma concentrations of insulin and glp-1 hormone (glucagon-like peptide 1) in healthy and diabetic wistar rats. |
2018-06-29 |
2023-08-13 |
rat |
| Ronald M Goldenberg, Lori Berar. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. Current medical research and opinion. vol 34. issue 1. 2018-06-27. PMID:28836861. |
adding prandial glp-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. |
2018-06-27 |
2023-08-13 |
Not clear |
| Ronald M Goldenberg, Lori Berar. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. Current medical research and opinion. vol 34. issue 1. 2018-06-27. PMID:28836861. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) have recently shown promise as useful additions to basal insulin, with significant reductions in glycated hemoglobin and potentially beneficial effects on body weight. |
2018-06-27 |
2023-08-13 |
Not clear |
| Ronald M Goldenberg, Lori Berar. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. Current medical research and opinion. vol 34. issue 1. 2018-06-27. PMID:28836861. |
this review will focus on pivotal clinical trials to assess the potential benefits of adding prandial glp-1 ras to basal insulin in patients with t2dm. |
2018-06-27 |
2023-08-13 |
Not clear |
| B Vergè. Effects of anti-somatostatin agents on glucose metabolism. Diabetes & metabolism. vol 43. issue 5. 2018-06-25. PMID:28579289. |
pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of glp-1 and gip, and potentially also due to a direct inhibitory effect of pasireotide on beta cells. |
2018-06-25 |
2023-08-13 |
Not clear |
| Sudha S Shankar, R Ravi Shankar, Lori A Mixson, Deborah L Miller, Barnali Pramanik, Amy K O'Dowd, Donna M Williams, Clay B Frederick, Chan R Beals, S Aubrey Stoch, Helmut O Steinberg, David E Kelle. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes. Diabetes. vol 67. issue 6. 2018-06-25. PMID:29545266. |
infusion of native oxm on insulin secretion rates (isrs) and glycemic excursion in a graded glucose infusion (ggi) procedure in two separate randomized, placebo (pbo)-controlled, single-dose crossover trials in 12 overweight and obese subjects without diabetes and in 12 obese subjects with type 2 diabetes mellitus (t2dm), using the glp-1 analog liraglutide (lira) as a comparator in t2dm. |
2018-06-25 |
2023-08-13 |
human |
| Sudha S Shankar, R Ravi Shankar, Lori A Mixson, Deborah L Miller, Barnali Pramanik, Amy K O'Dowd, Donna M Williams, Clay B Frederick, Chan R Beals, S Aubrey Stoch, Helmut O Steinberg, David E Kelle. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes. Diabetes. vol 67. issue 6. 2018-06-25. PMID:29545266. |
our findings indicate that native oxm significantly augments glucose-dependent insulin secretion acutely in obese subjects with and without diabetes, with effects comparable to pharmacologic glp-1 receptor activation and independent of weight loss. |
2018-06-25 |
2023-08-13 |
human |
| Merlin C Thoma. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes & metabolism. vol 43 Suppl 1. 2018-06-22. PMID:28431667. |
these benefits may be consistent with the known effects of glp-1 ra on traditional risk factors for progressive kidney disease including glucose lowering, blood pressure lowering, reduced insulin levels and weight reduction. |
2018-06-22 |
2023-08-13 |
Not clear |
| B Vergès, B Charbonne. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes & metabolism. vol 43 Suppl 1. 2018-06-22. PMID:28431669. |
finally, as a reduction in insulin resistance has been associated with a decrease in cv risk, it cannot be ruled out that the lowering of insulin resistance induced by glp-1 receptor agonists might also be involved in their beneficial cv actions. |
2018-06-22 |
2023-08-13 |
Not clear |
| M Joubert, Y Rezni. Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure. Diabetes & metabolism. vol 43 Suppl 1. 2018-06-22. PMID:28431670. |
use of glp-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure. |
2018-06-22 |
2023-08-13 |
Not clear |
| Asuka Morita, Motoshi Ouchi, Misao Terada, Hiroe Kon, Satoko Kishimoto, Keitaro Satoh, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Ken-Ichi Inoue, Naohiko Anza. Reproducible insulin secretion from isolated rat pancreas preparations using an organ bath. Experimental animals. vol 67. issue 1. 2018-06-22. PMID:28757517. |
we found that insulin secretion significantly declined during incubation in the organ bath, whereas it was maintained in the presence of 1 µm glp-1. |
2018-06-22 |
2023-08-13 |
rat |
| James Flory, Tobias Gerhard, Nikita Stempniewicz, Scott Keating, Christopher G Rowa. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data. Diabetes, obesity & metabolism. vol 19. issue 8. 2018-06-19. PMID:28266807. |
the objective of this brief report is to compare adherence rates for 6 major classes of diabetes medications: metformin, sulfonylurea, thiazolidinedione, basal insulin, dpp-4 inhibitors, and glp-1 receptor agonists. |
2018-06-19 |
2023-08-13 |
Not clear |
| Yusaku Iwasaki, Chayon Goswami, Toshihiko Yad. Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. Neuropeptides. vol 65. 2018-06-14. PMID:28624122. |
intestinal glucagon-like peptide-1 (glp-1) and pancreatic insulin, released postprandially, commonly regulate glucose metabolism. |
2018-06-14 |
2023-08-13 |
mouse |